 BeyondSpring Inc. BYSI, -1.84 said Wednesday that it has received a complete response letter CRL from the U.S. Food and Drug Administration, saying the biopharmaceutical companys new drug application NDA for its treatment for chemotherapy-induced neutropenia CIN cannot be approved in its present form. The stock, which was up 5.7 prior to a trading halt for new, is set to resume trading at 8:30 a.m. 